Samyang Biopharm USA in-licenses Talix Therapeutics’ first-in-class compound
![](/46/pdcnewsitem/08/49/98/%EC‚%BC%EC–‘%20%EB‰%B4%EC%8A%A4%202.jpg)
Samyang Biopharm USA has licensed in Belgium’s Talix Therapeutics’ first-in-class immuno-oncology compound for global rights.
Under the agreement, Samyang Biopharmaceuticals’ subsidiary will gain the research rights, as well as exclusive options to worldwide rights for development, manufacturing and commercialization of Talix’s anti-CD96 antibody.
The anti-CD96 antibody is a first-in-class compound that is currently in preclinical phase. Samyang and Talix will jointly run the preclinical trials, and depending on the result, will carry out global clinical trials.Antibodies to CD96 have been reported to protect mice from tumors by activating T cells. In vivo studies, or studies done in living organisms, have reportedly shown evidence that such antibodies can synergize with PD-1 checkpoint blocking molecules that allows T cells to kill tumor cells.Samyang’s collaboration with Talix is the second partnership disclosed by the company in recent weeks. On Dec. 2, Samyang announced an exclusive global license-in of US-based CanCure’s first-in-class immune stimulatory monoclonal antibody targeting soluble MHC class 1 chain-related protein, a byproduct of tumor cells.
![Samyang Biopharmaceuticals Corp](https://www.cphi-online.com/th263846-comp263846.png)
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance